ABSL |
animal biosafety level |
ACE-2 receptor |
Angiotensin-converting enzyme 2 |
APHIS |
Animal and Plant Health Inspection Service |
BARDA |
Biomedical Advanced Research and Development Authority |
BMBL |
Biosafety in Microbiological and Biomedical Laboratories |
BSAT |
Biological Select Agents and Toxins |
BSL |
biosafety level |
CDC |
U.S. Centers for Disease Control and Prevention |
cDNA |
complementary deoxyribonucleic acid |
CoV |
coronavirus |
CRISPR |
clustered regularly interspaced short palindromic repeats |
DNA |
deoxyribonucleic acid |
DURC |
dual use research of concern |
EID |
Emerging Infectious Diseases |
FBI |
Federal Bureau of Investigation |
GAO |
Government Accountability Office |
GOF |
gain-of-function |
HA |
hemagglutinins |
HAE |
human airway epithelial |
HEPA |
high-efficiency particulate arrestance |
HPAIV |
highly pathogenic avian influenza viruses |
IACUC |
Institutional Animal Care and Use Committees |
IBC |
Institutional Biosafety Committee |
IOM |
Institute of Medicine |
IRI |
Influenza Research Institute (at the University of Wisconsin-Madison) |
JCVI |
J. Craig Venter Institute |
LAI |
Laboratory Acquired Infection |
mAb |
monoclonal antibody |
MERS |
Middle East respiratory syndrome |
NA |
neuraminidase |
NAS |
National Academy of Sciences |
NIAID |
National Institute of Allergy and Infectious Diseases |
NIH |
National Institutes of Health |
NSABB |
National Science Advisory Board for Biosecurity |
NRC |
National Research Council |
PLoS |
Public Library of Science |
PPE |
personal protective equipment |
PPP |
potential pandemic pathogens |
RNA |
ribonucleic acid |
SARS |
severe acute respiratory syndrome |
SGVI |
Synthetic Genomics Vaccines |
SL-CoV |
SARS-like CoV |
S&T |
science and technology |
UPMC |
University of Pittsburgh Medical Center |
USDA |
U.S. Department of Agriculture |
USG |
U.S. Government |
USNRC |
U.S. Nuclear Regulatory Commission |